UB Paderborn / Katalog / Suche / in CDI

Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer

Scientific reports, 2023-10, Vol.13 (1), p.16953-16953, Article 16953

2023

Volltextzugriff (PDF)

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Journal for immunotherapy of cancer, 2021-06, Vol.9 (6), p.e002057

2021

Volltextzugriff (PDF)

Pancreatic cancer: Update on immunotherapies and algenpantucel-L

Human vaccines & immunotherapeutics, 2016-03, Vol.12 (3), p.563-575

2016

Volltextzugriff (PDF)

Immunotherapy updates in pancreatic cancer: are we there yet?

Therapeutic Advances in Medical Oncology, 2013-01, Vol.5 (1), p.81-89

2013

Volltextzugriff (PDF)

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Clinical cancer research, 2023-09, Vol.29 (17), p.3514

2023

Volltextzugriff (PDF)

Algenpantucel-L immunotherapy in pancreatic adenocarcinoma

Immunotherapy, 2016-02, Vol.8 (2), p.117-125

2016

Volltextzugriff (PDF)

Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes

Cancer research (Chicago, Ill.), 2005-11, Vol.65 (22), p.10555-10561

2005

Volltextzugriff (PDF)

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens

Journal of immunotherapy (1997), 2013-01, Vol.36 (1), p.57

2013

Volltextzugriff (PDF)

Abstract PO-065: SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer

Cancer research (Chicago, Ill.), 2021-11, Vol.81 (22_Supplement), p.PO-065-PO-065

2021

Volltextzugriff (PDF)

Combination immunotherapy for high-risk resected and metastatic melanoma patients

The Ochsner journal, 2014, Vol.14 (2), p.164-174

2014

Volltextzugriff (PDF)

Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes

Cancer Immunology, Immunotherapy, 2005-10, Vol.54 (10), p.999-1009

2005

Volltextzugriff (PDF)

High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes

Human gene therapy, 2003-03, Vol.14 (4), p.385-391

2003

Volltextzugriff (PDF)

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.4015-4015

2018

Volltextzugriff (PDF)

NLG-0301: An open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS8133-TPS8133

2014

Volltextzugriff (PDF)

NLG-0304: A phase 2B study of ipilimumab with or without dorgenmeltucel-L (HyperAcute-Melanoma) immunotherapy for patients with stage IV melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS9115-TPS9115

2014

Volltextzugriff (PDF)

Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.TPS9117-TPS9117

2014

Volltextzugriff (PDF)

Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.8094-8094

2013

Volltextzugriff (PDF)

Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.3029-3029

2014

Volltextzugriff (PDF)

Correlation of interferon-g (IFN-γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.2571-2571

2012

Volltextzugriff (PDF)

Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3007-3007

2013

Volltextzugriff (PDF)

Final results of a phase II immunotherapy trial for stage III and IV melanoma patients

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.e19008-e19008

2012

Volltextzugriff (PDF)

Abstract 5507: Immunological findings in a phase II immunotherapy study using allogeneic lung cancer cells modified to express alpha(1,3)galactosyltransferase in advanced non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2011-04, Vol.71 (8_Supplement), p.5507-5507

2011

Volltextzugriff (PDF)

Abstract 2423: Phase I/II study of antitumor vaccination using lung cancer cells expressing murine α(1,3)galactosyltransferase (αGT) in non-small cell lung cancer (NSCLC)

Cancer research (Chicago, Ill.), 2010-04, Vol.70 (8_Supplement), p.2423-2423

2010

Volltextzugriff (PDF)

Allogeneic melanoma vaccine expressing alphaGal epitopes induce anti-tumor immunity to autologous melanoma antigens without signs of toxicity (48.7)

The Journal of immunology (1950), 2007-04, Vol.178 (1_Supplement), p.S75-S76

2007

Volltextzugriff (PDF)

Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity

Journal of immunotherapy (1997), 2008-07, Vol.31 (6), p.545

2008

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Advanced glycation end product (AGE) targeting antibody SIWA318H is efficacious in preclinical models for pancreatic cancer

Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma

Pancreatic cancer: Update on immunotherapies and algenpantucel-L

Immunotherapy updates in pancreatic cancer: are we there yet?

Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Algenpantucel-L immunotherapy in pancreatic adenocarcinoma

Effective treatment of preexisting melanoma with whole cell vaccines expressing α(1,3)-galactosyl epitopes

Cellular immunotherapy study of prostate cancer patients and resulting IgG responses to peptide epitopes predicted from prostate tumor-associated autoantigens

Abstract PO-065: SIWA318H, an advanced glycation end product (AGE) targeting antibody, is efficacious in a humanized mouse xenograft model for pancreatic cancer

Combination immunotherapy for high-risk resected and metastatic melanoma patients

Complete protection against melanoma in absence of autoimmune depigmentation after rejection of melanoma cells expressing α(1,3)galactosyl epitopes

High-efficiency lentiviral vector-mediated gene transfer into murine macrophages and activated splenic B lymphocytes

Phase 2 trial of the IDO pathway inhibitor indoximod plus gemcitabine / nab-paclitaxel for the treatment of patients with metastatic pancreas cancer

NLG-0301: An open-label, randomized phase 2B active control study of second-line tergenpumatucel-L immunotherapy versus docetaxel in patients with progressive or relapsed non-small cell lung cancer (NSCLC)

NLG-0304: A phase 2B study of ipilimumab with or without dorgenmeltucel-L (HyperAcute-Melanoma) immunotherapy for patients with stage IV melanoma

Phase 1/2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus ipilimumab for the treatment of unresectable stage 3 or 4 melanoma

Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC)

Correlation of anti-calreticulin antibody titers with improved overall survival in a phase 2 clinical trial of algenpantucel-L immunotherapy for patients with resected pancreatic cancer

Correlation of interferon-g (IFN-γ) response with survival in a phase II hyperacute (HAL) immunotherapy trial for non-small cell lung cancer (NSCLC)

Effect of algenpantucel-L immunotherapy for pancreatic cancer on anti-mesothelin antibody (Ab) titers and correlation with improved overall survival

Final results of a phase II immunotherapy trial for stage III and IV melanoma patients

Abstract 5507: Immunological findings in a phase II immunotherapy study using allogeneic lung cancer cells modified to express alpha(1,3)galactosyltransferase in advanced non-small cell lung cancer (NSCLC)

Abstract 2423: Phase I/II study of antitumor vaccination using lung cancer cells expressing murine α(1,3)galactosyltransferase (αGT) in non-small cell lung cancer (NSCLC)

Allogeneic melanoma vaccine expressing alphaGal epitopes induce anti-tumor immunity to autologous melanoma antigens without signs of toxicity (48.7)

Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity

Suchergebnisse filtern